Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Autolus Therapeutics (AUTL) Total Debt: 2018-2023

Historic Total Debt for Autolus Therapeutics (AUTL) over the last 2 years, with Sep 2023 value amounting to $295,000.

  • Autolus Therapeutics' Total Debt rose 180.95% to $295,000 in Q3 2023 from the same period last year, while for Sep 2023 it was $295,000, marking a year-over-year increase of 180.95%. This contributed to the annual value of $116,000 for FY2022, which is 9.38% down from last year.
  • Autolus Therapeutics' Total Debt amounted to $295,000 in Q3 2023, which was up 141.80% from $122,000 recorded in Q2 2023.
  • In the past 5 years, Autolus Therapeutics' Total Debt ranged from a high of $295,000 in Q3 2023 and a low of $30,000 during Q3 2019.
  • In the last 3 years, Autolus Therapeutics' Total Debt had a median value of $119,000 in 2022 and averaged $139,875.
  • Its Total Debt has fluctuated over the past 5 years, first declined by 9.38% in 2022, then spiked by 180.95% in 2023.
  • Over the past 4 years, Autolus Therapeutics' Total Debt (Quarterly) stood at $30,000 in 2019, then reached $128,000 in 2021, then dropped by 9.38% to $116,000 in 2022, then skyrocketed by 180.95% to $295,000 in 2023.
  • Its last three reported values are $295,000 in Q3 2023, $122,000 for Q2 2023, and $114,000 during Q1 2023.